Published in Transplantation
The immunosuppressive effects of MPA (medroxyprogesterone acetate) were tested in clinical studies with laboratory dogs and rabbits. The laboratory procedures employed in the studies are explained and results are tabulated and graphed. 2 microscopic photographs illustrate the observed effects. MPA significantly prolonged the survival of dogs with r...
Published in Research in veterinary science
Clinical studies were carried out with laboratory female rats to ascertain the effects of daily dosing with MPA (medroxyprogesterone acetate). Some of the rats received .8 mg MPA in 1.4 ml acqueous suspension. The others received 2 mg MPA in intramuscular injections. The doses used were those necessary for estrus synchronisation. Body weight was in...
Published in Bangladesh Medical Research Council bulletin
Clinical research was carried out to assess the effects of 2 longacting injectable contraceptives on the ovaries and uteri of female virgin rats. 2 different doses of DMPA (depo-medroxyprogesterone acetate) and NE (norethisterone enanthate) and 2 control substances were used in the study. The laboratory procedures employed are explained and the res...
Published in Pharmacological research communications
A clinical study with 361 female rats was conducted to elucidate the mechanism whereby MPA (medroxyprogesterone acetate) lowers 5-HT/5-HIAA ratio in the brain area and the possible role of serotoniergic mechanisms. In addition, the participation of MAO (monoamino oxidase) system and the effects of some steroids were studied in order to establish a ...
Published in The Journal of endocrinology
Three experiments were conducted to evaluate the duration of activity of a long-acting progestin, medroxyprogesterone acetate: 1) induction of stromal mitosis in the endometrium; 2) implantation of blastocysts; and 3) inhibition of ovulation. In the 1st experiment, randomly bred albino mice were ovariectomized and injected with MPA 1 week later. Th...
Published in Indian journal of experimental biology
Clinical experimentation was carried out to assess the antiestrogenic effects of norethindrone and depo provera administered at a dose schedule which did not inhibit ovulation. The laboratory procedures employed are explained and results tabulated. Norethindrone at doses of 10, 25, and 50 ug/rat daily for 10 days and depo-provera at doses of 1, 5, ...
Published in Indian journal of biochemistry & biophysics
Clinical experimentation was carried out to assess the effect of nonantiovulatory doses of norethindrone and depo provera on implantation in rats. Norethindrone in doses of 25 and 50 mcg and depo provera in doses of 5 and 10 mcg, administered from day 0-5 of pregnancy, prevented implantation. Lower doses of either drug had no effect on implantation...
Published in Nursing times
The contraceptive effect of Depo-Provera or medroxyprogesterone acetate, a long-acting injectable progestogen, has been mainly attributed to its ability to prevent ovulation through its action on the hypothalamic pituitary axis, reducing the levels of plasma gonadotropin, progesterone, and estradiol, and suppressing the midcycle surge of luteinizin...
Published in Acta endocrinologica
Published in Papua and New Guinea medical journal
In this discussion of Depo-Provera (DMPA) attention is directed to the following: pharmacology and mode of action; clinical considerations; cervical dysplasia; breast cancer; and endometrial carcinoma. DMPA, a microcrystalline suspension of medroxy-progesterone acetate, is used widely around the world as a contraceptive, particularly in developing ...
